PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Sino Biopharmaceutical Ltd (1177.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG8167W1380
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$58.06B
EPSHK$0.01
PE Ratio28.09
PEG Ratio0.49
Revenue (TTM)HK$26.20B
Gross Profit (TTM)HK$21.53B
EBITDA (TTM)HK$6.38B
Year RangeHK$2.29 - HK$3.98
Target PriceHK$4.53

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Sino Biopharmaceutical Ltd

Popular comparisons: 1177.HK vs. 6078.HK

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Sino Biopharmaceutical Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


150.00%200.00%250.00%300.00%December2024FebruaryMarchAprilMay
208.55%
270.92%
1177.HK (Sino Biopharmaceutical Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Sino Biopharmaceutical Ltd had a return of -14.99% year-to-date (YTD) and -24.52% in the last 12 months. Over the past 10 years, Sino Biopharmaceutical Ltd had an annualized return of -6.67%, while the S&P 500 had an annualized return of 10.87%, indicating that Sino Biopharmaceutical Ltd did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-14.99%11.56%
1 month26.07%7.13%
6 months-22.37%17.26%
1 year-24.52%26.92%
5 years (annualized)-15.89%13.56%
10 years (annualized)-6.67%10.87%

Monthly Returns

The table below presents the monthly returns of 1177.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-19.02%11.39%-3.51%-10.60%-14.99%
2023-0.44%-10.99%8.64%-1.37%-14.05%-7.12%3.23%-15.34%-5.03%8.22%26.32%-9.64%-22.28%
2022-1.83%-7.09%-1.81%-15.13%6.26%13.81%-8.65%-8.81%-9.51%3.25%20.21%-0.22%-14.19%
2021-3.60%19.36%-9.85%7.58%4.18%-12.39%-13.39%-1.36%-0.48%-10.84%-1.22%-4.04%-26.80%
2020-4.40%8.25%-9.40%10.96%7.58%19.79%-30.82%-11.39%-5.48%-7.35%-0.26%-3.56%-30.77%
201927.91%3.18%5.14%5.31%4.91%1.20%21.15%20.45%-14.47%17.67%-13.82%8.06%112.18%
20184.04%2.77%3.91%8.44%18.80%-39.27%-10.96%-7.28%-26.45%-3.70%1.57%-27.60%-62.62%
201712.64%8.94%-4.48%-0.00%8.59%-0.62%0.10%-0.43%20.38%10.29%12.28%35.62%154.86%
2016-24.93%7.36%2.28%-5.15%-4.53%-3.92%2.57%-3.86%4.75%4.22%-2.03%2.76%-22.26%
201510.53%-5.15%6.51%13.12%3.49%-1.97%-0.11%2.34%3.53%1.79%-24.56%-3.36%0.63%
20146.99%9.57%-8.32%-8.17%4.12%-0.47%6.21%7.05%8.32%1.04%-1.79%-8.29%14.63%
20134.88%15.24%21.52%-1.29%1.68%-7.37%12.13%-1.77%-5.18%4.19%11.70%0.70%67.14%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 1177.HK is 18, indicating that it is in the bottom 18% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of 1177.HK is 1818
1177.HK (Sino Biopharmaceutical Ltd)
The Sharpe Ratio Rank of 1177.HK is 1515Sharpe Ratio Rank
The Sortino Ratio Rank of 1177.HK is 1515Sortino Ratio Rank
The Omega Ratio Rank of 1177.HK is 1717Omega Ratio Rank
The Calmar Ratio Rank of 1177.HK is 2626Calmar Ratio Rank
The Martin Ratio Rank of 1177.HK is 1515Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Sino Biopharmaceutical Ltd (1177.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


1177.HK
Sharpe ratio
The chart of Sharpe ratio for 1177.HK, currently valued at -0.62, compared to the broader market-2.00-1.000.001.002.003.004.00-0.62
Sortino ratio
The chart of Sortino ratio for 1177.HK, currently valued at -0.75, compared to the broader market-4.00-2.000.002.004.006.00-0.75
Omega ratio
The chart of Omega ratio for 1177.HK, currently valued at 0.92, compared to the broader market0.501.001.502.000.92
Calmar ratio
The chart of Calmar ratio for 1177.HK, currently valued at -0.30, compared to the broader market0.002.004.006.00-0.30
Martin ratio
The chart of Martin ratio for 1177.HK, currently valued at -1.17, compared to the broader market-10.000.0010.0020.0030.00-1.17
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.34, compared to the broader market-2.00-1.000.001.002.003.004.002.34
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.31, compared to the broader market-4.00-2.000.002.004.006.003.31
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.93, compared to the broader market-10.000.0010.0020.0030.008.93

Sharpe Ratio

The current Sino Biopharmaceutical Ltd Sharpe ratio is -0.62. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Sino Biopharmaceutical Ltd with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.62
2.34
1177.HK (Sino Biopharmaceutical Ltd)
Benchmark (^GSPC)

Dividends

Dividend History

Sino Biopharmaceutical Ltd granted a 2.71% dividend yield in the last twelve months. The annual payout for that period amounted to HK$0.08 per share.


PeriodTTM20232022202120202019201820172016201520142013
DividendHK$0.08HK$0.08HK$0.10HK$0.04HK$0.05HK$0.04HK$0.04HK$0.03HK$0.03HK$0.02HK$0.02HK$0.01

Dividend yield

2.71%2.31%2.19%0.73%0.71%0.37%0.77%0.22%0.49%0.25%0.27%0.24%

Monthly Dividends

The table displays the monthly dividend distributions for Sino Biopharmaceutical Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06HK$0.00HK$0.00HK$0.00HK$0.02HK$0.00HK$0.00HK$0.08
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.04HK$0.00HK$0.00HK$0.06HK$0.00HK$0.00HK$0.00HK$0.10
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.02HK$0.00HK$0.00HK$0.02HK$0.00HK$0.00HK$0.00HK$0.04
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.02HK$0.00HK$0.00HK$0.02HK$0.05
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.04
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.04
2017HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.01HK$0.00HK$0.01HK$0.00HK$0.01HK$0.00HK$0.03
2016HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.01HK$0.03
2015HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.02
2014HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.02
2013HK$0.01HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.01

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%2.7%
Sino Biopharmaceutical Ltd has a dividend yield of 2.71%, which is quite average when compared to the overall market.
Payout Ratio
20.0%40.0%60.0%80.0%100.0%120.0%11.5%
Sino Biopharmaceutical Ltd has a payout ratio of 11.46%, which is below the market average. This means Sino Biopharmaceutical Ltd returns a smaller proportion of its earnings to shareholders as dividends, suggesting it retains a higher portion for reinvestment, growth, or debt payment.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-84.52%
0
1177.HK (Sino Biopharmaceutical Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Sino Biopharmaceutical Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Sino Biopharmaceutical Ltd was 87.72%, occurring on Apr 19, 2024. The portfolio has not yet recovered.

The current Sino Biopharmaceutical Ltd drawdown is 84.52%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-87.72%May 29, 20181452Apr 19, 2024
-81.11%Apr 27, 20041064Oct 27, 2008384May 14, 20101448
-54.98%Nov 9, 2015155Jun 24, 2016341Nov 10, 2017496
-52.11%May 17, 2010475Apr 17, 2012165Dec 11, 2012640
-38.05%Oct 3, 20004Oct 9, 200093Feb 28, 200197

Volatility

Volatility Chart

The current Sino Biopharmaceutical Ltd volatility is 15.28%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%December2024FebruaryMarchAprilMay
15.28%
3.13%
1177.HK (Sino Biopharmaceutical Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Sino Biopharmaceutical Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items